Related Experiment Video

Updated: Jun 25, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

Elevated cord blood IgE is associated with recurrent wheeze and atopy at 7 yrs in a high risk cohort

Alexander Ferguson1, Helen Dimich-Ward, Allan Becker

  • 1Division of Allergy, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.

Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology
|February 25, 2009
PubMed

Insights

Detecting immunoglobulin E (IgE) in cord blood may help identify infants at high risk for developing allergic diseases. This cord blood IgE measure shows potential for primary prevention strategies in atopic children.

Area of Science:

  • Immunology
  • Pediatrics
  • Allergy Research

Background:

  • Primary prevention of atopic diseases requires identifying high-risk children early.
  • Family history is a key indicator for children at increased risk of allergic diseases.

Purpose of the Study:

  • To evaluate risk factors associated with detectable cord blood IgE (CB-IgE).
  • To assess the predictive value of CB-IgE for asthma and other IgE-mediated allergic diseases in high-risk children.

Main Methods:

  • Cord blood samples were collected from infants enrolled in a primary prevention randomized controlled trial.
  • CB-IgE levels were measured and analyzed for associations with perinatal risk factors.
  • The cohort was followed up to age 7 to assess atopic disorder development and the predictive utility of CB-IgE.

Main Results:

  • Detectable CB-IgE (≥0.5 kU/l) was found in 19.3% of infants.
  • Maternal atopy and winter birth were identified as risk factors for detectable CB-IgE.
  • CB-IgE was significantly associated with allergic sensitization (OR 2.22) and recurrent wheeze at age 7 (OR 2.51).

Conclusions:

  • CB-IgE may serve as a valuable biomarker for identifying infants predisposed to atopic diseases.
  • This finding supports the use of CB-IgE in primary prevention programs for allergic conditions.

More Related Videos

A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma06:34

A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma

Published on: June 4, 2017

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)

Published on: April 21, 2019

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

Overview
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: